SV investment has resulted in the approval of 24 novel therapeutics
SV News
28 November 2023Portfolio NewsHarness Therapeutics secures additional £4 million funding to pursue physiological upregulation approach to treat neurodegenerative diseases
21 November 2023Portfolio NewsDementia Discovery Fund Announces the Acquisition of Caraway Therapeutics by Merck- 21 November 2023Portfolio NewsMerck to Acquire Caraway Therapeutics, Inc.
14 November 2023Portfolio NewsTransposon Announces Interim Results from a Phase 2 Study of TPN-101 for the Treatment of Progressive Supranuclear Palsy to be Presented at the AD/PD™ 2024 International Conference on Alzheimer's and Parkinson's Diseases
14 November 2023Portfolio NewsEyeBio Announces Expansion of Series A to $130 Million, Advances Development of Restoret for Retinal Diseases
13 November 2023Portfolio NewsCerevance Doses First Patient in ASCEND Phase 2 Clinical Study of CVN424, a First-in-Class, Non-Dopaminergic Therapy for the Treatment of Parkinson’s Disease
12 November 2023Portfolio NewsImbria Reports Positive Topline Results for Investigational New Drug Ninerafaxstat in Patients with Cardiac Ischemia and Chronic Stable Angina- 7 November 2023Portfolio NewsImbria Reports Positive Topline Results for Investigational New Drug Ninerafaxstat in Patients with Non-obstructive Hypertrophic Cardiomyopathy
6 November 2023Portfolio NewsAviadoBio Announces FDA IND Clearance and Fast Track Designation for AVB-101 for the Treatment of Frontotemporal Dementia with Progranulin (GRN) Mutations
1 November 2023Portfolio NewsSitryx announces partner Lilly exercises option to SIT-011 for chronic autoimmune and inflammatory diseases
18 October 2023Portfolio NewsCumulus Neuroscience to Present Data at CTAD 2023 Annual Meeting
16 October 2023Portfolio NewsPulmocide Announces New Clinical Data Confirming Low Potential for Drug-Drug Interactions with Inhaled Opelconazole
